Valuation: Reshape Lifesciences Inc

Market Cap 14.74M 12.83M 12.11M 11M 20.61M 1.41B 20.71M 145M 55.95M 719M 55.36M 54.13M 2.31B P/E 2026 *
-3.68x
P/E 2027 * -2.63x
Enterprise Value 14.74M 12.83M 12.11M 11M 20.61M 1.41B 20.71M 145M 55.95M 719M 55.36M 54.13M 2.31B EV / Sales 2026 *
111x
EV / Sales 2027 * 73.7x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 133K 116K 110K 99.55K 186K 12.78M 187K 1.31M 506K 6.5M 501K 490K 20.91M 200K 174K 164K 149K 280K 19.17M 281K 1.97M 759K 9.75M 751K 735K 31.37M
Net income -4M -3.48M -3.29M -2.99M -5.59M -383M -5.62M -39.32M -15.19M -195M -15.02M -14.69M -627M -7.85M -6.83M -6.45M -5.86M -10.97M -752M -11.02M -77.12M -29.79M -383M -29.47M -28.82M -1.23B
Net Debt - -
Logo Reshape Lifesciences Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!